Literature DB >> 5447717

The use of radioactive phosphorus to treat bone pain in metastatic carcinoma of the prostate.

A Morales, R C Burr, A W Bruce.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5447717      PMCID: PMC1930435     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  7 in total

1.  THE USE OF P32 IN THE TREATMENT OF SEVERE PAIN FROM BONE METASTASES OF CARCINOMA OF THE PROSTATE.

Authors:  J G SMART
Journal:  Br J Urol       Date:  1965-04

2.  Experiences with P-32 in treatment of metastatic carcinoma of prostate: a preliminary report.

Authors:  R L PARSONS
Journal:  J Urol       Date:  1961-03       Impact factor: 7.450

3.  Radioactive isotopes and nuclear radiations in the treatment of cancer.

Authors:  J H LAWRENCE; C A TOBIAS
Journal:  Cancer Res       Date:  1956-03       Impact factor: 12.701

4.  Modifying effect of steroid hormone therapy of human neoplastic disease as judged by radioactive phosphorous (P32) studies.

Authors:  S HERTZ
Journal:  J Clin Invest       Date:  1950-06       Impact factor: 14.808

5.  Testosterone potentiated 32P therapy in prostatic carcinoma.

Authors:  R M Donati; H Ellis; N I Gallagher
Journal:  Cancer       Date:  1966-08       Impact factor: 6.860

6.  Radioactive phosphorus in the treatment of metastasis to bone from carcinoma of the prostate.

Authors:  L J Morin; J C Stevens
Journal:  J Urol       Date:  1967-01       Impact factor: 7.450

7.  Stimulation of hematopoiesis by androgenic hormones.

Authors:  B J Kennedy
Journal:  Geriatrics       Date:  1965-10
  7 in total
  6 in total

1.  [Endo-osseous isotope therapy of malignant skeletal disease (author's transl)].

Authors:  N Firusian
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1978-05-31

2.  Addressing the pressing issues related to testosterone administration to men with prostate cancer.

Authors:  Alvaro Morales
Journal:  Can Urol Assoc J       Date:  2016 May-Jun       Impact factor: 1.862

3.  Androgen priming and cytotoxic chemotherapy in advanced prostatic cancer.

Authors:  A J Suarez; D L Lamm; H M Radwin; M Sarosdy; G Clark; C K Osborne
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Adenocarcinoma of the prostate in perspective.

Authors:  A W Bruce; D E Mahan
Journal:  Can Med Assoc J       Date:  1978-11-04       Impact factor: 8.262

Review 5.  Androgen therapy in the aging male.

Authors:  Bruno Lunenfeld
Journal:  World J Urol       Date:  2003-10-24       Impact factor: 4.226

6.  Strontium 89 for palliation of bone metastases.

Authors:  E K Reddy; R G Robinson; C M Mansfield
Journal:  J Natl Med Assoc       Date:  1986-01       Impact factor: 1.798

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.